CN110241459A - A kind of immune group library method screening sample room and being reacted with independent sample crossover - Google Patents
A kind of immune group library method screening sample room and being reacted with independent sample crossover Download PDFInfo
- Publication number
- CN110241459A CN110241459A CN201910468845.6A CN201910468845A CN110241459A CN 110241459 A CN110241459 A CN 110241459A CN 201910468845 A CN201910468845 A CN 201910468845A CN 110241459 A CN110241459 A CN 110241459A
- Authority
- CN
- China
- Prior art keywords
- primer
- seq
- nucleotide sequence
- receptor
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000012216 screening Methods 0.000 title claims description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 54
- 239000002299 complementary DNA Substances 0.000 claims abstract description 33
- 238000012408 PCR amplification Methods 0.000 claims abstract description 26
- 230000003321 amplification Effects 0.000 claims abstract description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 23
- 238000012163 sequencing technique Methods 0.000 claims abstract description 11
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 11
- 238000010839 reverse transcription Methods 0.000 claims abstract description 3
- 239000002773 nucleotide Substances 0.000 claims description 209
- 125000003729 nucleotide group Chemical group 0.000 claims description 209
- 239000000203 mixture Substances 0.000 claims description 201
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 58
- 239000000047 product Substances 0.000 claims description 57
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 28
- 101100437372 Mus musculus Bcr gene Proteins 0.000 claims description 28
- 101100437373 Rattus norvegicus Bcr gene Proteins 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 19
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000002474 experimental method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000012264 purified product Substances 0.000 claims description 4
- 238000000197 pyrolysis Methods 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims 1
- 238000010276 construction Methods 0.000 abstract description 12
- 238000013461 design Methods 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 description 107
- 102000005962 receptors Human genes 0.000 description 107
- 241000282414 Homo sapiens Species 0.000 description 39
- 238000010586 diagram Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 1
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100029454 T cell receptor alpha chain MC.7.G5 Human genes 0.000 description 1
- 102100026967 T cell receptor beta chain MC.7.G5 Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of immune group library methods that examination sample room is reacted with independent sample crossover, it is characterized by: making RNA carry out template switch when carrying out reverse transcription into cDNA using the principle of RACE, 2 pre- amplifications are carried out before PCR amplification, pre- amplification is so that the end 5` of original template has taken UMI for the first time, second of pre- amplification is so that the end 3` of template has taken UMI, PCR amplification is carried out using this product with both-end UMI as template again, the upstream and downstream primer used simultaneously designs Barcode and PCR amplification is marked, finally obtained product obtains final sequencing library by purifying and connecting sequence measuring joints sequence, this method realizes the independent marking to each sequence, similar sequences be can solve in sample in pcr amplification reaction The cross reaction problem of generation, for the sample in different cell receptor sources, it is able to achieve in PCR amplification and only uses pair of primers progress PCR amplification, realize equivalent amplification, it solves the problems, such as the primer Preference generated because multi-primers expand, solves the problems, such as multiple samples while carrying out the cross reaction of the sample room of appearance when library construction.
Description
Technical field
The invention belongs to biological medicine service fields, more particularly, to a kind of PCR amplification in people's immune group library, library construction
And the application in next-generation sequencing, especially a kind of immune group library side screening sample room and being reacted with independent sample crossover
Method.
Background technique
Immune system is mediated by immunized B cells and the surface receptor of T cell, with antigen derived from pathogen or pathogen
In conjunction with, and then play immune function and body is protected not encroached on.BCR heavy chain immunoglobulin (IGH) and TCR β chain (TCRB) are logical
V gene is crossed, the rearrangement of D gene and J constant gene segment C is to generate combination diversity.Junction between V-D and D-J lacks core
Thuja acid and at random addition nucleotide sequence produce receptor connection diversity.And light chain caused by antibody mediated immunity, ball is immunized
T cell receptor α (TCRA) during albumen λ or κ (IGL/K) and T cell are immune, which has, similarly to be reset, so as to form siberian crabapple
The diversity of system.It is in y-type structure by the antibody that immune group library B cell generates by taking antibody mediated immunity group library as an example, it is identical by two
Heavy chain and light chain composition.V (D) J recombinate when, it is V, D, J section multiple in respectively have a meeting be selected and recombinate, form a weight
The variable region of chain.And the upstream of the V section of front end, the sequence including ATG are known as the boot section of antibody.Each different V
Gene section corresponds to different guidance region sequences, target area (such as specification of the end 5` primer when which is the amplification of antibody group library
Shown in attached drawing 1).Similarly, we are by having found the guidance of TCR receptor sequence to the research in T cell surface receptor structure
Area, the target area as the end TCR sequence 5` design of primers.
Using high throughput sequencing technologies come to the analysis by the immune group library in blood or lymphoid organ, to be exceedingly fast
Speed develops and is increasing our cognitions to immune response.Such as immunoglobulin gene high throughput DNA sequencing is obtained
The information obtained can be used for detecting B cell malignant tumour in high sensitivity, finds the antibody special to target antigen, vaccine is instructed to open
Hair and understanding autoimmunity etc..Therefore, the research using high-flux sequence analysis method to immune group library can promote us right
Immunologic understanding and the solution method for not meeting clinical demand relevant to infectious disease, immune disorder and cancer.
Currently, there are mainly two types of existing people's immune group library PCR amplification and library construction techniques.1. based on multiplex PCR
Library constructing method: using DNA or cDNA as template, a plurality of upstream primer is designed for boot section, for different antibody phenotypes
It is expanded in constant region one downstream primer of design, amplification using the combination of many-to-one primer, then carries out library construction simultaneously
Sequencing.2. the library constructing method based on 5`RACE: using mRNA as template, being synthesized using the overall length that oligodT carries out cDNA, needle
To the special construction at the end 5` of mRNA, one section of universal sequence can be introduced at the end 5` simultaneously in the synthesis of cDNA, then using general
Sequence as upstream primer, and constant region design a downstream primer, expanded using pair of primers, finally carry out text
Library constructs and is sequenced.
Although the quick high throughput of next generation's sequencing technologies energy carries out panorama type scanning to immune group library, at present
There are still more clearly disadvantageous for two methods.1. multiple PCR method has used a variety of primers, reaction system complex；It is more
Weight design of primers can only be designed according to known reference sequences, cannot be captured completely all etc. in the immune group library of full people
Position gene；More primer reactions can not accomplish equivalent amplification, and the amplification efficiency difference between different primers results in PCR Preference
In the presence of making result with truth, there are larger differences.2. although simple 5`RACE method can accomplish equivalent amplification,
It cannot distinguish between the cross reaction of the sequence in independent sample when building library.3. existing sequencing analysis method and experimental technique
There is no mitigation chimera sequence product as caused by the PCR later period, bring influences, and these products are two kinds of amplification sides
Can exist in method, and great interference, and existing technology and analysis side are produced to the diversity quantitative analysis in sample
Method can not screen most of cross products sequence, can generate interference to our sample sequence, generate the sequence between sample
Error.
The application is designed for the problem that current problem carries out completely new PCR method, be can solve and is currently encountered, and is reached true
The purpose of positive reduction immune group library truth.
Summary of the invention
The sample room that is generated during it is an object of the invention to screen people's immune group library PCR amplification and library construction and
The cross reaction of similar sequences in sample can after completing PCR amplification so as to really restore the truth in immune group library
Multiple samples or sample room are merged one library of building, solve what similar sequences in sample were generated in pcr amplification reaction
Cross reaction problem, for the sample in different cell receptor sources, the upstream and downstream primer used in PCR amplification is designed by 4-
The Barcode of 12 different bases composition is marked, and solves multiple samples while carrying out the sample of appearance when library construction
Between cross reaction the problem of.Unless otherwise defined, all technical and scientific terms used herein have and institute of the present invention
Belong to the normally understood identical meaning of those of ordinary skill of technical field.
Term:
UMI full name is unique molecular identifiers, is made of randomized bases, the UMI that the present invention designs
Structure be N (10) structure, length 10bp, random number 410It is a, there is fabulous randomness；
Barcode: bar code herein refers to the known particular sequence of 4-12bp composition.
5 end rapid amplifying of 5`RACE:5`Rapid Amplification of cDNA Ends, cDNA.
The present invention is the principle of gene 5'RACE, the pre- amplification of a wheel twice is carried out before PCR amplification, so that every cDNA
Both ends all mark different and unique UMI sequence, the upstream and downstream primer used in PCR amplification is designed by 4-12
The Barcode of different bases composition is marked, and multiple samples can be closed and occur and construct a library.
It is a kind of to screen the immune group library method reacted with independent sample crossover of sample room, it is characterised in that: including with
Lower step:
The preparation of S1, cDNA template: using the RNA greater than 10ng as initial amount, make RNA inverse in progress using the principle of RACE
Template switch is carried out when being transcribed into cDNA into cDNA；
S2, then cDNA template carry out 2 pre- amplifications before PCR amplification, and pre- amplification is drawn using the upstream with UMI for the first time
Object forms product A so that the end 5` of original template has taken UMI；
S3, product A is carried out second of pre- amplification, using the downstream primer with UMI, so that the end 3` of template takes
UMI forms product B；
S4, again using the product B with both-end UMI in step S3 as template, reuse both-end Barcode primer progress
PCR amplification finally obtains product C；
Final product C obtained in S5, step S4 obtains final sequencing text by purifying and connecting sequence measuring joints sequence
Library.
In described step S1, S2, S3, the S4, the upstream primer expanded in advance for the first time, the downstream primer expanded in advance for the second time
And the primer sequence of PCR amplification totally 104, as shown in sequence table.
It is prepared by the cDNA template of the S1 include the following:
(1) cell RNA extracts: cell origin includes but is not limited to that the peripheral blood of people or mouse, rat and rabbit separates
The lymphocyte arrived, number of cells are that cell pyrolysis liquid is added and is cracked, is carried out using RNA extracts kit greater than 100
The extracting of RNA；
(2) tissue RNA is extracted: the tumor tissues and normal tissue or come that tissue-derived including but not limited to manpower art is got off
Derived from the various organization types of mouse, rat and rabbit, initial amount be greater than 1mg, using be added after liquid nitrogen grinding lysate into
Row cracking, the extracting of RNA is carried out using RNA extracts kit；
(3) Quality Identification and Concentration Testing are carried out to mRNA, it is desirable that the result of mRNA is complete, and RNA total amount is greater than 10ng；
(4) in order to improve the yield of cDNA, we are to have done optimization processing early period in synthesis cDNA, according to the configuration of such as following table
Mixed system, and being reacted in PCR instrument, response procedures are as follows: 70 DEG C, 1min, immediately product is put after response procedures
In 3min on ice；
(5) mixed system for configuring following table is reacted, reaction interval with being placed in PCR instrument after the mixing of the product of step (4)
Sequence are as follows: 42 DEG C, 90min, 75 DEG C, 15min, 4 DEG C, ∞.Product after reaction is synthetic cDNA template, will be used for next
Step experiment；
The pre- amplification condition of cDNA template first of the S2 include the following:
(1) the PCR reaction system such as following table is configured；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, reaction product is purified, is finally washed with 20ul Nuclease-free water
It is de-, obtain product A.
The product A of the S3 carries out the second pre- amplification condition include the following:
(1) the PCR reaction system such as following table is configured, product A is divided into 4 equal portions, while carrying out 4 reactions；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, obtained product is reacted 4 and be mixed to get the product that a general pipeline adds up to 200ul, to this
Product is purified, and is finally eluted with 20ul Nuclease-free water, obtains product B.
The step S4 carries out PCR amplification using both-end Barcode primer, include the following:
(1) PCR reaction is carried out by template of the purified product B of step S3, prepares reaction system according to following table；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, which is purified, is finally washed with 30ul Nuclease-free water
It is de-, obtain product C.
The primer sequence requires as follows:
The nucleotide sequence of RACE oligo includes or is made of SEQ ID NO:1, and wherein the 4 of end G is ribose core
Guanine in acid；
The nucleotide sequence of Primer 1 in step 2 includes or is made of SEQ ID NO:2；
When receptor behaviour BCR IgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:3 composition；
When receptor behaviour BCR IgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:4 composition；
When receptor behaviour BCR IgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:5 composition；
When receptor behaviour BCR IgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:6 composition；
When receptor behaviour BCR IgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:7 composition；
When receptor behaviour BCR IgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:8 composition；
When receptor behaviour BCR IgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:9 composition；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:10 composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:11 composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:12 composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:13 composition；
When receptor is mouse BCR IgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:14 composition；
When receptor is mouse BCR IgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:15 composition；
When receptor is mouse BCR IgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:16 composition；
When receptor is mouse BCR IgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:17 composition；
When receptor is mouse BCR IgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:18 composition；
When receptor is mouse BCR IgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:19 composition；
When receptor is mouse BCR IgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:20 composition；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:21 composition；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:22 composition；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:23 composition；
When receptor is rat BCR IgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:24 composition；
When receptor is rat BCR IgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:25 composition；
When receptor is rat BCR IgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:26 composition；
When receptor is rat BCR IgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:27 composition；
When receptor is rat BCR IgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:28 composition；
When receptor is rat BCR IgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:29 composition；
When receptor is rat BCR IgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:30 composition；
When receptor is rabbit BCR IgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:31 composition；
When receptor is rabbit BCR IgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:32 composition；
When receptor is rabbit BCR IgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:33 composition；
When receptor is rabbit BCR IgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:34 composition；
When receptor is rabbit BCR IgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:35 composition；
When receptor is rabbit BCR IgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID
NO:36 composition；
When receptor behaviour BCR IgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:37 composition；
When receptor behaviour BCR IgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:38 composition；
When receptor behaviour BCR IgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:39 composition；
When receptor behaviour BCR IgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:40 composition；
When receptor behaviour BCR IgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:41 composition；
When receptor behaviour BCR IgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:42 composition；
When receptor behaviour BCR IgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:43 composition；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:44 composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:45 composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:46 composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:47 composition；
When receptor is mouse BCR IgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:48 composition；
When receptor is mouse BCR IgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:49 composition；
When receptor is mouse BCR IgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:50 composition；
When receptor is mouse BCR IgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:51 composition；
When receptor is mouse BCR IgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:52 composition；
When receptor is mouse BCR IgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:53 composition；
When receptor is mouse BCR IgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:54 composition；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:55 composition；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:56 composition；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:57 composition；
When receptor is rat BCR IgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:58 composition；
When receptor is rat BCR IgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:59 composition；
When receptor is rat BCR IgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:60 composition；
When receptor is rat BCR IgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:61 composition；
When receptor is rat BCR IgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:62 composition；
When receptor is rat BCR IgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:63 composition；
When receptor is rat BCR IgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:64 composition；
When receptor is rabbit BCR IgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:65 composition；
When receptor is rabbit BCR IgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:66 composition；
When receptor is rabbit BCR IgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:67 composition；
When receptor is rabbit BCR IgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:68 composition；
When receptor is rabbit BCR IgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:69 composition；
When receptor is rabbit BCR IgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID
NO:70 composition；
When receptor behaviour BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:71 composition；
When receptor behaviour BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:72 composition；
When receptor behaviour BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:73 composition；
When receptor behaviour BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:74 composition；
When receptor behaviour BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:75 composition；
When receptor behaviour BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:76 composition；
When receptor behaviour BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:77 composition；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:78 composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:79 composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:80 composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:81 composition；
When receptor is mouse BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:82 composition；
When receptor is mouse BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:83 composition；
When receptor is mouse BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:84 composition；
When receptor is mouse BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:85 composition；
When receptor is mouse BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:86 composition；
When receptor is mouse BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:87 composition；
When receptor is mouse BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:88 composition；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:89 composition；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:90 composition；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:91 composition；
When receptor is rat BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:92 composition；
When receptor is rat BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:93 composition；
When receptor is rat BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:94 composition；
When receptor is rat BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:95 composition；
When receptor is rat BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:96 composition；
When receptor is rat BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:97 composition；
When receptor is rat BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:98 composition；
When receptor is rabbit BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:99 composition；
When receptor is rabbit BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:100 composition；
When receptor is rabbit BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:101 composition；
When receptor is rabbit BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:102 composition；
When receptor is rabbit BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:103 composition；
When receptor is rabbit BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID
NO:104 composition.
The invention has the benefit that
(1) while RNA reverse transcription is at cDNA, utilization expands in advance twice, adds simultaneously at the end 5` and the end 3` of cDNA
UMI realizes the independent marking to each sequence, can solve what similar sequences in sample were generated in pcr amplification reaction
Cross reaction problem.
(2) sample in different cell receptor sources is able to achieve in PCR amplification such as BCR or TCR and only uses one
PCR amplification is carried out to primer, realizes equivalent amplification, solves the problems, such as the primer Preference generated because multi-primers expand.
(3) upstream and downstream primer used in PCR amplification is designed is carried out by the Barcode that 4-12 different bases form
Label, solves the problems, such as multiple samples while carrying out the cross reaction of the sample room of appearance when library construction.
(4) present invention can meet the sample requirement for construction data base that RNA concentration is greater than 10ng.
Detailed description of the invention
Fig. 1 is heavy chain of antibody VDJ regrouping process schematic diagram；
Fig. 2 is cDNA preparation and PCR schematic diagram；
The datagram diagram 1 in the library of Fig. 3 test；
The datagram diagram 2 in the library of Fig. 4 test.
Specific embodiment
The explanation of following embodiment is merely used to help understand method and its core concept of the invention, it is noted that right
For those skilled in the art, without departing from the principle of the present invention, the present invention can also be carried out
Some improvements and modifications, such as design of primers or adjustment of the length in 18bp to 30bp of 200bp progress are originated in constant region domains
Base quantity of UMI etc., these improvements and modifications also fall within the scope of protection of the claims of the present invention.To disclosed implementation
The following the description of example, enables those skilled in the art to implement or use the present invention.Various modifications to these embodiments
It will be readily apparent to those skilled in the art, the general principles defined herein can not depart from this
In the case where the spirit or scope of invention, realize in other embodiments.Therefore, the present invention is not intended to be limited to illustrated herein
These embodiments in, but can be applied to meet broader model consistent with the principles and novel features disclosed in this article
It encloses.
1 1ml human peripheral sample immune group library high-throughput sequencing library construction method of embodiment
The preparation of 1.cDNA template
(1) human peripheral 1ml is acquired using EDTA anticoagulant tube, using single core in density gradient centrifugation method separation blood
Cell, is added 600ul cell pyrolysis liquid and carries out cell cracking, carries out RNA extracting using RNA extracts kit.
(2) integrality for detecting RNA, measures the concentration of RNA.
(3) mixed system is configured according to the following table 9, and is reacted in PCR instrument, response procedures are as follows: 70 DEG C, 1min, instead
Product is immediately put in 3min on ice after answering EP (end of program).Table 9
(4) mixed system for configuring the following table 10 is reacted with being placed in PCR instrument after the mixing of the product of step (3), is reacted
Program are as follows: 42 DEG C, 90min, 75 DEG C, 15min, 4 DEG C, ∞.Product after reaction is synthetic cDNA template, will be used for down
The experiment of one step.Table 10
First time pre- amplified reaction before 2.PCR
(1) the PCR reaction system such as the following table 11 is configured.Table 11
The primer sequence of Primer 5 are as follows:
CATGGACCTTACGACTAGCT(NNNNNNNNNN)4-12AAGCAGTGGTATCAACGCAGAG
(2) PCR response procedures such as the following table 12: table 12
(3) after the reaction was completed, reaction product is purified, is finally washed with 20ul Nuclease-free water
It is de-, obtain product D.
Second of pre- amplified reaction before 3.PCR
(1) the PCR reaction system such as the following table 13 is configured, product D is divided into 4 equal portions, while carrying out 4 reactions.Table 13
The primer sequence of Primer 6 are as follows:
ACTCGAAGTTCAGTCG(NNNNNNNNNN)4-12GGGGAAGACCGATGGGCCCTTGGTGG
(2) PCR response procedures such as the following table 14: table 14
(3) after the reaction was completed, obtained product is reacted 4 and be mixed to get the product that a general pipeline adds up to 200ul, to this
Product is purified, and is finally eluted with 20ul Nuclease-free water, obtains product E.
4.PCR reaction.
(1) PCR reaction is carried out by template of the purified product E of step (3), prepares reaction system according to table 15.Table 15
The primer sequence of Primer 7 are as follows: TCCTGAGCCATGGACCTTACGACTAGCT
The primer sequence of Primer 8 are as follows: AAGGAGTAGACTAGGAACTCGAAGTTCAGTCG
(2) PCR response procedures such as the following table 16: table 16
(3) after the reaction was completed, which is purified, is finally washed with 30ul Nuclease-free water
It is de-, obtain product F.
5. constructing sequencing library
(1) product F is subjected to connector connection using library construction Kit；
(2) library fragments screen and identify the quality in library using magnetic bead, as a result following table 17.
The immune group library high-throughput sequencing library of embodiment 2:1mg human breast carcinoma tissue sample constructs
The preparation of 1.cDNA template
(1) human breast carcinoma tissue sample is taken out from liquid nitrogen or -80 DEG C of refrigerators, 1mg is weighed, using the method handle of liquid nitrogen grinding
Tissue grinder is added 600ul cell pyrolysis liquid and carries out cell cracking, RNA extracts kit is used to carry out RNA pumping at powdered
It mentions.
(2) integrality for detecting RNA, measures the concentration of RNA.
(3) mixed system is configured according to the following table 18, and is reacted in PCR instrument, response procedures are as follows: 70 DEG C, 1min, instead
Product is immediately put in 3min on ice after answering EP (end of program).Table 18
(4) mixed system for configuring the following table 19 is reacted with being placed in PCR instrument after the mixing of the product of step (3), is reacted
Program are as follows: 42 DEG C, 90min, 75 DEG C, 15min, 4 DEG C, ∞.Product after reaction is synthetic cDNA template, will be used for down
The experiment of one step.Table 19
First time pre- amplified reaction before 2.PCR
(1) the PCR reaction system such as the following table 20 is configured.Table 20
The primer sequence of Primer 9 are as follows: CATGGACCTTACGACTAGCT (NNNNNNNNNN)4- 12AAGCAGTGGTATCAACGCAGAG
(2) PCR response procedures such as the following table 21: table 21
(3) after the reaction was completed, reaction product is purified, is finally washed with 20ul Nuclease-free water
It is de-, obtain product G.
Second of pre- amplified reaction before 3.PCR
(1) the PCR reaction system such as the following table 22 is configured, product G is divided into 4 equal portions, while carrying out 4 reactions.
Table 22
The primer sequence of Primer 10 are as follows:
ACTCGAAGTTCAGTCG(NNNNNNNNNN)4-12GGGGAAGACCGATGGGCCCTTGGTGG
(2) PCR response procedures such as the following table 25:
Table 25
(3) after the reaction was completed, obtained product is reacted 4 and be mixed to get the product that a general pipeline adds up to 200ul, to this
Product is purified, and is finally eluted with 20ul Nuclease-free water, obtains product H.
4.PCR reaction.
(1) PCR reaction is carried out by template of the purified product H of step (3), prepares reaction system according to table 26.
Table 26
The primer sequence of Primer 11 are as follows: TCCTGAGCCATGGACCTTACGACTAGCT
The primer sequence of Primer 12 are as follows: AAGGAGTAGACTAGGAACTCGAAGTTCAGTCG
(2) PCR response procedures such as the following table 27: table 27
(3) after the reaction was completed, which is purified, is finally washed with 30ul Nuclease-free water
It is de-, obtain product I.
5. constructing sequencing library
(1) product I is subjected to connector connection using library construction Kit；
(2) library fragments screen and identify the quality in library using magnetic bead, as a result following table 28.
Table 28
Embodiment 3
By the combined application of both-end barcode and both-end UMI, we can carry out more accurately school to sequencing sample
Just with screening, PCR and sequencing mistake are removed, the accuracy of sample sequence, the data cases in 14 libraries of test are improved
As shown in table 29 and attached drawing 3 and Fig. 4.Table 29:
As shown in table 29, Fig. 3,4, we pass through the combined application of both-end barcode and both-end UMI technology, greatly subtract
Lacked PCR error and sequencing mistake influence with causing, alleviate data analysis in brought ground error as a result, for antibody group library
Subsequent quantitative and analysis has risen and has established solid foundation.
7.cDNA preparation and PCR schematic diagram, as shown in Figure 2.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case where without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power
Benefit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent elements of the claims
Variation is included within the present invention.
In addition, it should be understood that although this specification is described in terms of embodiments, but not each embodiment is only wrapped
Containing an independent technical solution, this description of the specification is merely for the sake of clarity, and those skilled in the art should
It considers the specification as a whole, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
The other embodiments being understood that.
Sequence table
<110>Hospital of Southern Medical University
<120>a kind of immune group library method screening sample room and being reacted with independent sample crossover
<141> 2019-05-31
<160> 104
<170> SIPOSequenceListing 1.0
<210> 1
<211> 26
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 1
aagcagtggt atcaacgcag aggggg 26
<210> 2
<211> 52
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (21)..(30)
<223> n is a, c, g or t
<400> 2
catggacctt acgactagct nnnnnnnnnn aagcagtggt atcaacgcag ag 52
<210> 3
<211> 44
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 3
actcgaagtt cagtcgnnnn nnnnnnggct cagcgggaag acct 44
<210> 4
<211> 47
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 4
actcgaagtt cagtcgnnnn nnnnnngtgt ctgcaccctg atatgat 47
<210> 5
<211> 50
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 5
actcgaagtt cagtcgnnnn nnnnnnagac ggatgggctc tgtgtggagg 50
<210> 6
<211> 52
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 6
actcgaagtt cagtcgnnnn nnnnnngggg aagaccgatg ggcccttggt gg 52
<210> 7
<211> 44
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 7
actcgaagtt cagtcgnnnn nnnnnnttgg ggcggatgca ctcc 44
<210> 8
<211> 46
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 8
actcgaagtt cagtcgnnnn nnnnnnagat ggtgcagcca cagttc 46
<210> 9
<211> 56
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 9
actcgaagtt cagtcgnnnn nnnnnncctt gttggcttgr agctcctcag aggagg 56
<210> 10
<211> 46
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 10
actcgaagtt cagtcgnnnn nnnnnncagg gtcagggttc tggata 46
<210> 11
<211> 46
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 11
actcgaagtt cagtcgnnnn nnnnnntctg atggctcaaa cacagc 46
<210> 12
<211> 46
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 12
actcgaagtt cagtcgnnnn nnnnnngatg gtttggtatg aggctg 46
<210> 13
<211> 46
<212> DNA
<213>artificial sequence (Homo sapiens)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 13
actcgaagtt cagtcgnnnn nnnnnntatg ttccagcctt ctggag 46
<210> 14
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 14
actcgaagtt cagtcgnnnn nnnnnnaggt cacattcatc gtgccg 46
<210> 15
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 15
actcgaagtt cagtcgnnnn nnnnnngcac tctgagagga ggaaca 46
<210> 16
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 16
actcgaagtt cagtcgnnnn nnnnnnggtc atggaagcag tgcctt 46
<210> 17
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 17
actcgaagtt cagtcgnnnn nnnnnngaca gggatccaga gttcca 46
<210> 18
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 18
actcgaagtt cagtcgnnnn nnnnnngcac cagattctta tcagac 46
<210> 19
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 19
actcgaagtt cagtcgnnnn nnnnnngayt gaggcacctc cagatg 46
<210> 20
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 20
actcgaagtt cagtcgnnnn nnnnnnagct cttcagagga aggtgg 46
<210> 21
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 21
actcgaagtt cagtcgnnnn nnnnnnaact ggtacacagc aggttc 46
<210> 22
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 22
actcgaagtt cagtcgnnnn nnnnnnggtg gagtcacatt tctcag 46
<210> 23
<211> 47
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 23
actcgaagtt cagtcgnnnn nnnnnncaat cttcttggat gatctga 47
<210> 24
<211> 45
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 24
actcgaagtt cagtcgnnnn nnnnnngtct cagtgggtag atggt 45
<210> 25
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 25
actcgaagtt cagtcgnnnn nnnnnngagg aacaagtcag gttcct 46
<210> 26
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<400> 26
actcgaagtt cagtcgnnnn nnnnnntttc gctgctacag ggcttc 46
<210> 27
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 27
actcgaagtt cagtcgnnnn nnnnnnagac agatggggct gttgtt 46
<210> 28
<211> 49
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 28
actcgaagtt cagtcgnnnn nnnnnnccac caaattctca tcagacagg 49
<210> 29
<211> 46
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 29
actcgaagtt cagtcgnnnn nnnnnngata cagttggtgc agcatc 46
<210> 30
<211> 47
<212> DNA
<213>artificial sequence (Mouse)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 30
actcgaagtt cagtcgnnnn nnnnnntggg agtggacttg ggctgac 47
<210> 31
<211> 46
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 31
actcgaagtt cagtcgnnnn nnnnnngatc aggcagccga ygacca 46
<210> 32
<211> 45
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 32
actcgaagtt cagtcgnnnn nnnnnnctct gcagcaggag gccaa 45
<210> 33
<211> 46
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 33
actcgaagtt cagtcgnnnn nnnnnncggt cttgtccact ttggtg 46
<210> 34
<211> 46
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 34
actcgaagtt cagtcgnnnn nnnnnngtac agagttggag atgaca 46
<210> 35
<211> 46
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 35
actcgaagtt cagtcgnnnn nnnnnntggt gggaagakga ggacag 46
<210> 36
<211> 48
<212> DNA
<213>artificial sequence (Rabbit)
<220>
<221> misc_feature
<222> (17)..(26)
<223> n is a, c, g or t
<400> 36
actcgaagtt cagtcgnnnn nnnnnngggt agaagtcayt gatcagac 48
<210> 37
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 37
taaggcgaca tggaccttac gactagct 28
<210> 38
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 38
cgtactagca tggaccttac gactagct 28
<210> 39
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 39
aggcagaaca tggaccttac gactagct 28
<210> 40
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 40
tcctgagcca tggaccttac gactagct 28
<210> 41
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 41
ggactcctca tggaccttac gactagct 28
<210> 42
<211> 27
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 42
taggcatcat ggaccttacg actagct 27
<210> 43
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 43
ctctctacca tggaccttac gactagct 28
<210> 44
<211> 27
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 44
cgaggctcat ggaccttacg actagct 27
<210> 45
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 45
ctattaagca tggaccttac gactagct 28
<210> 46
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 46
aaggctatca tggaccttac gactagct 28
<210> 47
<211> 28
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 47
gagccttaca tggaccttac gactagct 28
<210> 48
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 48
taaggcgaca tggaccttac gactagct 28
<210> 49
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 49
cgtactagca tggaccttac gactagct 28
<210> 50
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 50
aggcagaaca tggaccttac gactagct 28
<210> 51
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 51
tcctgagcca tggaccttac gactagct 28
<210> 52
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 52
ggactcctca tggaccttac gactagct 28
<210> 53
<211> 27
<212> DNA
<213>artificial sequence (Mouse)
<400> 53
taggcatcat ggaccttacg actagct 27
<210> 54
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 54
ctctctacca tggaccttac gactagct 28
<210> 55
<211> 27
<212> DNA
<213>artificial sequence (Mouse)
<400> 55
cgaggctcat ggaccttacg actagct 27
<210> 56
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 56
ctattaagca tggaccttac gactagct 28
<210> 57
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 57
aaggctatca tggaccttac gactagct 28
<210> 58
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 58
taaggcgaca tggaccttac gactagct 28
<210> 59
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 59
cgtactagca tggaccttac gactagct 28
<210> 60
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 60
aggcagaaca tggaccttac gactagct 28
<210> 61
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 61
tcctgagcca tggaccttac gactagct 28
<210> 62
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 62
ggactcctca tggaccttac gactagct 28
<210> 63
<211> 27
<212> DNA
<213>artificial sequence (Mouse)
<400> 63
taggcatcat ggaccttacg actagct 27
<210> 64
<211> 28
<212> DNA
<213>artificial sequence (Mouse)
<400> 64
ctctctacca tggaccttac gactagct 28
<210> 65
<211> 28
<212> DNA
<213>artificial sequence (Rabbit)
<400> 65
taaggcgaca tggaccttac gactagct 28
<210> 66
<211> 28
<212> DNA
<213>artificial sequence (Rabbit)
<400> 66
cgtactagca tggaccttac gactagct 28
<210> 67
<211> 28
<212> DNA
<213>artificial sequence (Rabbit)
<400> 67
aggcagaaca tggaccttac gactagct 28
<210> 68
<211> 28
<212> DNA
<213>artificial sequence (Rabbit)
<400> 68
tcctgagcca tggaccttac gactagct 28
<210> 69
<211> 28
<212> DNA
<213>artificial sequence (Rabbit)
<400> 69
ggactcctca tggaccttac gactagct 28
<210> 70
<211> 27
<212> DNA
<213>artificial sequence (Rabbit)
<400> 70
taggcatcat ggaccttacg actagct 27
<210> 71
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 71
tatcctctga ctaggaactc gaagttcagt cg 32
<210> 72
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 72
gtaaggagga ctaggaactc gaagttcagt cg 32
<210> 73
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 73
actgcataga ctaggaactc gaagttcagt cg 32
<210> 74
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 74
aaggagtaga ctaggaactc gaagttcagt cg 32
<210> 75
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 75
ctaagcctga ctaggaactc gaagttcagt cg 32
<210> 76
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 76
cgtctaatga ctaggaactc gaagttcagt cg 32
<210> 77
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 77
tctctccgga ctaggaactc gaagttcagt cg 32
<210> 78
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 78
tcgactagga ctaggaactc gaagttcagt cg 32
<210> 79
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 79
ttctagctga ctaggaactc gaagttcagt cg 32
<210> 80
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 80
cctagagtga ctaggaactc gaagttcagt cg 32
<210> 81
<211> 32
<212> DNA
<213>artificial sequence (Homo sapiens)
<400> 81
gcgtaagaga ctaggaactc gaagttcagt cg 32
<210> 82
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 82
tatcctctga ctaggaactc gaagttcagt cg 32
<210> 83
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 83
gtaaggagga ctaggaactc gaagttcagt cg 32
<210> 84
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 84
actgcataga ctaggaactc gaagttcagt cg 32
<210> 85
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 85
aaggagtaga ctaggaactc gaagttcagt cg 32
<210> 86
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 86
ctaagcctga ctaggaactc gaagttcagt cg 32
<210> 87
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 87
cgtctaatga ctaggaactc gaagttcagt cg 32
<210> 88
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 88
tctctccgga ctaggaactc gaagttcagt cg 32
<210> 89
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 89
tcgactagga ctaggaactc gaagttcagt cg 32
<210> 90
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 90
ttctagctga ctaggaactc gaagttcagt cg 32
<210> 91
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 91
cctagagtga ctaggaactc gaagttcagt cg 32
<210> 92
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 92
tatcctctga ctaggaactc gaagttcagt cg 32
<210> 93
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 93
gtaaggagga ctaggaactc gaagttcagt cg 32
<210> 94
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 94
actgcataga ctaggaactc gaagttcagt cg 32
<210> 95
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 95
aaggagtaga ctaggaactc gaagttcagt cg 32
<210> 96
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 96
ctaagcctga ctaggaactc gaagttcagt cg 32
<210> 97
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 97
cgtctaatga ctaggaactc gaagttcagt cg 32
<210> 98
<211> 32
<212> DNA
<213>artificial sequence (Mouse)
<400> 98
tctctccgga ctaggaactc gaagttcagt cg 32
<210> 99
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 99
tatcctctga ctaggaactc gaagttcagt cg 32
<210> 100
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 100
gtaaggagga ctaggaactc gaagttcagt cg 32
<210> 101
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 101
actgcataga ctaggaactc gaagttcagt cg 32
<210> 102
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 102
aaggagtaga ctaggaactc gaagttcagt cg 32
<210> 103
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 103
ctaagcctga ctaggaactc gaagttcagt cg 32
<210> 104
<211> 32
<212> DNA
<213>artificial sequence (Rabbit)
<400> 104
cgtctaatga ctaggaactc gaagttcagt cg 32
Claims (7)
1. a kind of immune group library method screening sample room and being reacted with independent sample crossover, it is characterised in that: including following
Step:
The preparation of S1, cDNA template: using the RNA greater than 10ng as initial amount, RNA is made to carry out reverse transcription using the principle of RACE
At progress template switch when cDNA at the cDNA of one section of anchor tip of band；
S2, then cDNA template carry out 2 pre- amplifications before PCR amplification, and pre- amplification uses the upstream primer with UMI for the first time,
So that the end 5` of original template has taken UMI, product A is formed；
S3, it is purified after, product A is carried out second pre- amplification, using the downstream primer with UMI, so that the end the 3` band of template
UMI has been gone up, product B is formed；
S4, it is purified after, using the product B with both-end UMI in step S3 as template, reuse both-end Barcode primer
PCR amplification is carried out, product C is finally obtained；
Final product C obtained in S5, step S4 obtains final sequencing library by purifying and connecting sequence measuring joints sequence.
2. a kind of a kind of examination independent sample crossover reaction described in claim 1 is prepared according to claim 1
Immune group library method, it is characterised in that: in described step S1, S2, S3, the S4, for the first time expand in advance upstream primer, second
The primer sequence of the secondary downstream primer expanded in advance and PCR amplification totally 104, as shown in sequence table.
3. a kind of a kind of examination independent sample crossover reaction described in claim 1 is prepared according to claim 1
Immune group library method, which is characterized in that it is prepared by the cDNA template of the S1 include the following:
(1) cell RNA extracts: cell origin includes but is not limited to that the peripheral blood of people or mouse, rat and rabbit is isolated
Lymphocyte, number of cells are that cell pyrolysis liquid is added and is cracked greater than 100, carry out RNA using RNA extracts kit
Extracting；
(2) tissue RNA is extracted: tissue-derived includes but is not limited to the tumor tissues that get off of manpower art and normal tissue or derive from
The various organization types of mouse, rat and rabbit, initial amount are to be split greater than 1mg using lysate is added after liquid nitrogen grinding
Solution carries out the extracting of RNA using RNA extracts kit；
(3) Quality Identification and Concentration Testing are carried out to mRNA, it is desirable that the result of mRNA is complete, and RNA total amount is greater than 10ng；
(4) in order to improve the yield of cDNA, we are to have done optimization processing early period in synthesis cDNA, according to the configuration mixing of such as following table
System, and being reacted in PCR instrument, response procedures are as follows: 70 DEG C, 1min, product is immediately put in ice after response procedures
Upper 3min；
(5) mixed system for configuring following table is reacted, response procedures with being placed in PCR instrument after the mixing of the product of step (4)
Are as follows: 42 DEG C, 90min, 75 DEG C, 15min, 4 DEG C, ∞.Product after reaction is synthetic cDNA template, will be used in next step
Experiment；
4. a kind of a kind of examination independent sample crossover reaction described in claim 1 is prepared according to claim 2
Immune group library method, it is characterised in that: the pre- amplification condition of cDNA template first of the S2 include the following:
(1) the PCR reaction system such as following table is configured；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, reaction product is purified, is finally eluted with 20ul Nuclease-free water,
Obtain product A.
5. a kind of a kind of examination independent sample crossover reaction described in claim 1 is prepared according to claim 2
Immune group library method, it is characterised in that: the product A of the S3 carries out the second pre- amplification condition include the following:
(1) the PCR reaction system such as following table is configured, product A is divided into 4 equal portions, while carrying out 4 reactions；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, obtained product is reacted 4 and be mixed to get the product that a general pipeline adds up to 200ul, to the product
It is purified, is finally eluted with 20ul Nuclease-free water, obtain product B.
6. a kind of a kind of examination independent sample crossover reaction described in claim 1 is prepared according to claim 2
Immune group library method, it is characterised in that: using both-end Barcode primer carry out PCR amplification, include the following:
(1) PCR reaction is carried out by template of the purified product B of step S3, prepares reaction system according to following table；
(2) PCR response procedures are as follows:
(3) after the reaction was completed, which is purified, is finally eluted, is obtained with 30ul Nuclease-free water
To product C.
7. a kind of according to claim 3,4,5 or 6 prepare a kind of examination independent sample itself friendship described in claim 1
Pitch the immune group library method of reaction, it is characterised in that: the primer sequence requires as follows:
The nucleotide sequence of RACE oligo includes or is made of SEQ ID NO:1, and wherein the 4 of end G is in ribonucleic acid
Guanine；
The nucleotide sequence of Primer 1 in step 2 includes or is made of SEQ ID NO:2；
When receptor behaviour BCRIgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:3 group
At；
When receptor behaviour BCRIgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:4 group
At；
When receptor behaviour BCRIgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:5 group
At；
When receptor behaviour BCRIgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:6 group
At；
When receptor behaviour BCRIgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:7 group
At；
When receptor behaviour BCRIgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:8 group
At；
When receptor behaviour BCRIgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:9 group
At；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:10
Composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:11
Composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:12
Composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:13
Composition；
When receptor is mouse BCRIgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
14 compositions；
When receptor is mouse BCRIgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
15 compositions；
When receptor is mouse BCRIgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
16 compositions；
When receptor is mouse BCRIgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
17 compositions；
When receptor is mouse BCRIgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
18 compositions；
When receptor is mouse BCRIgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
19 compositions；
When receptor is mouse BCRIgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
20 compositions；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
21 compositions；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
22 compositions；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
23 compositions；
When receptor is rat BCRIgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
24 compositions；
When receptor is rat BCRIgD heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
25 compositions；
When receptor is rat BCRIgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
26 compositions；
When receptor is rat BCRIgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
27 compositions；
When receptor is rat BCRIgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
28 compositions；
When receptor is rat BCRIgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
29 compositions；
When receptor is rat BCRIgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
30 compositions；
When receptor is rabbit BCRIgA heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
31 compositions；
When receptor is rabbit BCRIgE heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
32 compositions；
When receptor is rabbit BCRIgG heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
33 compositions；
When receptor is rabbit BCRIgM heavy chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
34 compositions；
When receptor is rabbit BCRIgK light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
35 compositions；
When receptor is rabbit BCRIgL light chain: the nucleotide sequence of the Primer 2 in step 3 includes or by SEQ ID NO:
36 compositions；
When receptor behaviour BCRIgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:37
Composition；
When receptor behaviour BCRIgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:38
Composition；
When receptor behaviour BCRIgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:39
Composition；
When receptor behaviour BCRIgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:40
Composition；
When receptor behaviour BCRIgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:41
Composition；
When receptor behaviour BCRIgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:42
Composition；
When receptor behaviour BCRIgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:43
Composition；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:44
Composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:45
Composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:46
Composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:47
Composition；
When receptor is mouse BCRIgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
48 compositions；
When receptor is mouse BCRIgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
49 compositions；
When receptor is mouse BCRIgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
50 compositions；
When receptor is mouse BCRIgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
51 compositions；
When receptor is mouse BCRIgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
52 compositions；
When receptor is mouse BCRIgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
53 compositions；
When receptor is mouse BCRIgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
54 compositions；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
55 compositions；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
56 compositions；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
57 compositions；
When receptor is rat BCRIgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
58 compositions；
When receptor is rat BCRIgD heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
59 compositions；
When receptor is rat BCRIgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
60 compositions；
When receptor is rat BCRIgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
61 compositions；
When receptor is rat BCRIgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
62 compositions；
When receptor is rat BCRIgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
63 compositions；
When receptor is rat BCRIgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
64 compositions；
When receptor is rabbit BCRIgA heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
65 compositions；
When receptor is rabbit BCRIgE heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
66 compositions；
When receptor is rabbit BCRIgG heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
67 compositions；
When receptor is rabbit BCRIgM heavy chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
68 compositions；
When receptor is rabbit BCRIgK light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
69 compositions；
When receptor is rabbit BCRIgL light chain: the nucleotide sequence of the Primer 3 in step 4 includes or by SEQ ID NO:
70 compositions；
When receptor behaviour BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:71
Composition；
When receptor behaviour BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:72
Composition；
When receptor behaviour BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:73
Composition；
When receptor behaviour BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:74
Composition；
When receptor behaviour BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:75
Composition；
When receptor behaviour BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:76
Composition；
When receptor behaviour BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:77
Composition；
When receptor behaviour TCR alpha chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:78
Composition；
When receptor behaviour TCR beta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:79
Composition；
When receptor behaviour TCR delta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:80
Composition；
When receptor behaviour TCR gama chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:81
Composition；
When receptor is mouse BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
82 compositions；
When receptor is mouse BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
83 compositions；
When receptor is mouse BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
84 compositions；
When receptor is mouse BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
85 compositions；
When receptor is mouse BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
86 compositions；
When receptor is mouse BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
87 compositions；
When receptor is mouse BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
88 compositions；
When receptor is mouse TCR alpha chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
89 compositions；
When receptor is mouse TCR beta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
90 compositions；
When receptor is mouse TCR delta chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
91 compositions；
When receptor is rat BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
92 compositions；
When receptor is rat BCR IgD heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
93 compositions；
When receptor is rat BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
94 compositions；
When receptor is rat BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
95 compositions；
When receptor is rat BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
96 compositions；
When receptor is rat BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
97 compositions；
When receptor is rat BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
98 compositions；
When receptor is rabbit BCR IgA heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
99 compositions；
When receptor is rabbit BCR IgE heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
100 compositions；
When receptor is rabbit BCR IgG heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
101 compositions；
When receptor is rabbit BCR IgM heavy chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
102 compositions；
When receptor is rabbit BCR IgK light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
103 compositions；
When receptor is rabbit BCR IgL light chain: the nucleotide sequence of the Primer 4 in step 4 includes or by SEQ ID NO:
104 compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910468845.6A CN110241459A (en) | 2019-05-31 | 2019-05-31 | A kind of immune group library method screening sample room and being reacted with independent sample crossover |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910468845.6A CN110241459A (en) | 2019-05-31 | 2019-05-31 | A kind of immune group library method screening sample room and being reacted with independent sample crossover |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110241459A true CN110241459A (en) | 2019-09-17 |
Family
ID=67885599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910468845.6A Pending CN110241459A (en) | 2019-05-31 | 2019-05-31 | A kind of immune group library method screening sample room and being reacted with independent sample crossover |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110241459A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112852936A (en) * | 2020-06-24 | 2021-05-28 | 广州华银健康医疗集团股份有限公司 | Method for analyzing sample lymphocyte or plasma cell by using immune repertoire sequencing method, application and kit thereof |
| CN113999891A (en) * | 2021-09-17 | 2022-02-01 | 广东省人民医院 | Method for constructing immune repertoire high-throughput sequencing library for removing chimera sequences in sample, and group of primers and kit |
| CN114277091A (en) * | 2021-09-17 | 2022-04-05 | 广东省人民医院 | Method for constructing high-quality immune repertoire library |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319332D0 (en) * | 2003-08-16 | 2003-09-17 | Astrazeneca Ab | Amplification |
| WO2014043813A1 (en) * | 2012-09-19 | 2014-03-27 | British Columbia Cancer Agency Branch | Immune repertoire profiling |
| WO2016044227A1 (en) * | 2014-09-15 | 2016-03-24 | Abvitro, Inc. | High-throughput nucleotide library sequencing |
| CN107779495A (en) * | 2017-10-31 | 2018-03-09 | 中国医学科学院肿瘤医院 | The construction method and kit of T cell antigen receptor diversity sequencing library |
| CN108893464A (en) * | 2018-07-13 | 2018-11-27 | 广州华银医学检验中心有限公司 | A kind of construction method of immune group library high-throughput sequencing library |
| CN109136329A (en) * | 2018-08-13 | 2019-01-04 | 湖南大地同年生物科技有限公司 | A kind of construction method of unimolecule label TCR immune group library high-throughput sequencing library |
-
2019
- 2019-05-31 CN CN201910468845.6A patent/CN110241459A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319332D0 (en) * | 2003-08-16 | 2003-09-17 | Astrazeneca Ab | Amplification |
| WO2014043813A1 (en) * | 2012-09-19 | 2014-03-27 | British Columbia Cancer Agency Branch | Immune repertoire profiling |
| WO2016044227A1 (en) * | 2014-09-15 | 2016-03-24 | Abvitro, Inc. | High-throughput nucleotide library sequencing |
| CN107779495A (en) * | 2017-10-31 | 2018-03-09 | 中国医学科学院肿瘤医院 | The construction method and kit of T cell antigen receptor diversity sequencing library |
| CN108893464A (en) * | 2018-07-13 | 2018-11-27 | 广州华银医学检验中心有限公司 | A kind of construction method of immune group library high-throughput sequencing library |
| CN109136329A (en) * | 2018-08-13 | 2019-01-04 | 湖南大地同年生物科技有限公司 | A kind of construction method of unimolecule label TCR immune group library high-throughput sequencing library |
Non-Patent Citations (2)
| Title |
|---|
| HEATHER: "Dynamic Perturbations of the T-Cell Receptor Repertoire in Chronic HIV Infection and following Antiretroviral Therapy", 《FRONTIERS IN IMMUNOLOGY》 * |
| TURCHANINOVA: "High-quality full-length immunoglobulin profiling with unique molecular barcoding", 《NATURE PROTOCOLS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112852936A (en) * | 2020-06-24 | 2021-05-28 | 广州华银健康医疗集团股份有限公司 | Method for analyzing sample lymphocyte or plasma cell by using immune repertoire sequencing method, application and kit thereof |
| CN113999891A (en) * | 2021-09-17 | 2022-02-01 | 广东省人民医院 | Method for constructing immune repertoire high-throughput sequencing library for removing chimera sequences in sample, and group of primers and kit |
| CN114277091A (en) * | 2021-09-17 | 2022-04-05 | 广东省人民医院 | Method for constructing high-quality immune repertoire library |
| CN113999891B (en) * | 2021-09-17 | 2024-01-16 | 广东省人民医院 | Methods, a set of primers and a kit for constructing an immune repertoire high throughput sequencing library that removes chimeric sequences in a sample |
| CN114277091B (en) * | 2021-09-17 | 2024-02-27 | 广东省人民医院 | Method for constructing high-quality immune repertoire library |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110257476A (en) | A kind of construction method of immune group library high-throughput sequencing library that screening sample room cross reaction | |
| CN110241459A (en) | A kind of immune group library method screening sample room and being reacted with independent sample crossover | |
| CN108949941A (en) | Low-frequency mutation detection method, kit and device | |
| Lenardo et al. | Characterization of the genes specifying two metacyclic variable antigen types in Trypanosoma brucei rhodesiense. | |
| WO2017028753A1 (en) | Multiplex pcr primer and application thereof | |
| CN108950083A (en) | The multiplex RT-PCR method of GETV, PEDV, TGEV, PDCoV and PoRV are detected simultaneously | |
| CN108893464A (en) | A kind of construction method of immune group library high-throughput sequencing library | |
| CN106754904A (en) | A kind of specific molecular label of cDNA and its application | |
| CN110241460A (en) | A kind of immune group library method for screening the reaction of independent sample crossover | |
| CN107779495B (en) | Construction method and kit of T cell antigen receptor diversity sequencing library | |
| CN110396534A (en) | The construction method of gene library, determined nucleic acid sample gene mutation detection method and kit | |
| CN109810976B (en) | The preparation method and application of pig Senecan virus full length infection clones | |
| CN106498090A (en) | A kind of test kit for detecting DNA mismatch repair system and application thereof | |
| CN112662762A (en) | Probe composition for detecting 5 tumors of digestive tract | |
| CN109487005A (en) | For expanding the primer of the intranasal tumour virus whole genome sequence of goat region | |
| CN109280696B (en) | Method for splitting mixed sample by SNP detection technology | |
| Fujinaga et al. | RD-114 virus: analysis of viral gene sequences in feline and human cells by DNA-DNA reassociation kinetics and RNA-DNA hybridization | |
| CN109971843A (en) | A kind of sequencing approach of unicellular transcript profile | |
| CN107190103A (en) | Multiple PCR primer group, kit and the method for three kinds of fishes virus are detected simultaneously | |
| Li et al. | Phylogenetic position of the marine ciliate, Cardiostomatella vermiforme (Kahl, 1928) Corliss, 1960 inferred from the complete SSrRNA gene sequence, with establishment of a new order Loxocephalida n. ord.(Ciliophora, Oligohymenophorea) | |
| CN106676117A (en) | Construction and authentication of newcastle disease virus overall-length cDNA clone | |
| CN108707653A (en) | Build the sequencing approach of variable region sequences library kits and variable region sequences | |
| CN106978512A (en) | RT PCR primers and its kit for detecting new bamboo rat source Ah card's pinta poison | |
| JP2001505417A (en) | Methods for identifying genes essential for organism growth | |
| CN109072287A (en) | The target specificity rna transcription method of DNA sequence dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |